Group B streptococci have long been recognized as significant pathogens in bovine mastitis and as opportunistic invaders of certain compromised human hosts (5, 16) . More recently, their role in neonatal disease has been emphasized, particularly in neonatal meningitis, a disease that has two syndromes: the rapidly fulminating with sudden onset of symptoms and a high mortality rate and the more insidious with delayed onset ( > 10 days) and a better prognosis (1-3, 6, 7, 10) . Death often precedes diagnosis of the acute form of the disease and identification of the Streptococcus (1, 10) . These infants usually obtain the organism from their mothers' vaginas during birth or, less frequently, by nosocomial transmission (1, 10) . Epidemiological factors concerning late onset group B meningitis are unknown. Further, reported carrier rates in gravid females (2, 10) vary widely, perhaps because of demographic differences, but more likely because of culture frequency and laboratory procedures. The attack rate in infants seems low (1, 10) , and this has prompted some clinicians to advise against the indiscriminate use of antibiotic prophylaxis (2, 8) .
The prognosis of neonatal meningitis is improved by prompt and adequate treatment (19) , which in turn depends on rapid identification of the streptococci. Conventional methods used to identify group B streptococci require a minimum of 2 days for presumptive tests (9) (18) to eliminate the R protein antigen of this strain (24) . This antigen occurs among streptococci of various groups and types (17, 22, 24) that might stain nonspecifically with conjugates that contain anti-R antibodies (13) . Each of 20 Evaluation of group B conjugate pool (B pool). Eight hundred and eighty-three consecutive isolates submitted for identification to the Streptococcus Laboratory, CDC, were tested with a 1: 2 dilution of the B pool. FA results were compared with those obtained with conventional culture-precipitin methods in the Streptococcus Laboratory. The culture methods included determination of hemolysis by viewing deep colonies in 5% rabbit blood agar pour plates with a dissecting microscope and determination of serological group and type by the capillaryprecipitin test using Lancefield extracts of betahemolytic strains (23, 26) . Todd-Hewitt broth cultures of 99 vaginal swabs obtained in an unrelated study were tested similarly in a double-blind study. Cells that stained at a 3 to 4+ level of intensity were considered positive in all studies.
Preservation and storage of conjugate. Conjugates were preserved with merthiolate (1: 10,000) and stored at 4 C. Stability of the B pool was tested weekly with vaccine strains and fresh isolates.
RESULTS
Twenty antisera (five sera for each of the four vaccine strains) were conjugated with FITC and titered ( Table 1) . Fluorescein-to-protein ratios ranged from 5 to 18 and titers from 2 to 32. 1:4) . The pool was diluted 1:2 before use. Densitometric traces and ultraviolet scans of type-specific and pooled conjugates subjected to electrophoresis revealed that in each conjugate most of the protein was globulin and that most of the FITC was bound to the globulin fraction (Fig. 1) .
Stock strains representing all Lancefield groups, viridans streptococci, pneumococci, and several other genera of bacteria frequently isolated from the genitourinary tract were used to test the specificity of the B pool (Table 3 ). All group B streptococci stained with 4+ intensity. All other organisms tested gave FA reactions of 2+ or less. Therefore, the same visual criteria could be used for a positive group B as for a 
aEach conjugate diluted to titer shown in Table 1 (20) . Figure 2 shows the fluorescence of a typical group B Streptococcus. The group B FA reagent was tested further by staining smears of 883 cultures isolated from clinical material and submitted to our laboratory for identification and by comparing the results with those obtained by conventional culture-precipitin techniques (Table 4 ). All 305 group B streptococci stained with an intensity of 3 to 4+. All other organisms gave negative reactions (2+ or less) except for five of 340 group A and three of 41 group C streptococci. Crossreactions of group A conjugate with streptococcal groups C and G and S. aureus can usually be eliminated by absorption with group C cells or by a one-step inhibition either with group C antiserum or with pools of normal rabbit serum (20, 21) . Absorption of the B pool with group C cells, however, diminished the group B reaction to an unacceptable level. Similarly, diluting the pool enough to reduce the cross-reaction also reduced the homologous reaction. Adding either normal rabbit serum or group C antiserum blocked the reaction with the five group A strains but not with the three cross-reacting group C strains. However, they represented only 7% of the group C strains tested and 0.3% of all the strains tested. There was complete agreement between results of FA and cultureprecipitin tests with all other isolates. Two observations deserve mention. First, cultureprecipitin methods failed to identify the group B streptococci in several mixed cultures in which the relative numbers of B streptococci were small. Positive FA reactions were confirmed by isolation of single colonies, followed by growth and HCl extraction of the streptococci. Second, culture-precipitin methods did not identify several nonhemolytic group B streptococci. Positive FA reactions were later confirmed by precipitin and biochemical tests.
Todd-Hewitt broth cultures of vaginal swabs that had been collected in a study by the Bureau of Epidemiology, CDC, were used to test further the specificity of the B conjugate. Weekly stability tests showed that the group B conjugate pool was stable at 4 C for at least 6 months. DISCUSSION These data suggest that identification of group B streptococci by the FA technique is feasible. Data obtained in a clinical setting are needed to show if the technique is efficacious. Data thus far on prevalence, incidence (1, 2, 16), prophylaxis, treatment (2, 6, 8) , and immunity (6, 16) indicate that the technique would be useful.
Five precautions must be taken to produce a sensitive specific group B conjugate. First, the conjugate must contain labeled antibodies specific for antigens on the surface of the streptococcal cell, i.e., the type antigens. Moody and Wilkinson (unpublished data) found that conjugated group B antisera often failed to give a positive FA reaction unless type-specific antibodies were included in the conjugate. Each antiserum should be labeled and titered individually, and its final dilution in the pool should be its predetermined titer; this would assure the same fluorescence intensity for each type and a comparable reduction in nonspecific staining and cross-reactions by dilution. Second, the conjugate cannot contain antibodies specific for R protein antigens that occur in other groups. Only a 63% agreement between results of FA and culture techniques was obtained in a study with anti-R-containing conjugates (14) . Third, the conjugate should contain antibodies specific for the group B antigen, since occasional nontypable B strains are found. They represent approximately 1% of the group B streptococci isolated from human sources (unpublished data). The B pool used in this study contained group B antibodies present in the four constituent conjugates and thus stained nontypable strains. Strains that contained type antigens, however, failed to stain with conjugates other than those made with homologous type antisera. These observations support the hypothesis that type antigens on the surface of the streptococcal cell block the group B antigen-antibody reaction, perhaps by steric hindrance. Fourth, conjugates should be free of albumin and unbound FITC to reduce nonspecific staining and fluorescence. Fifth, and last, group B conjugates must be tested with large numbers of heterologous organisms to assure specificity.
In the present study, no cross-reactions occurred with the stock strains tested. Only eight cross-reactions occurred in testing 982 clinical specimens: five with group A streptococci which were blocked with either group C antiserum or pooled normal rabbit serum and three with group C streptococci which could not be blocked, for unknown reasons. These "falsepositive" reactions were offset by the detection, with FA, of nine nonhemolytic group B streptococci which were initially not detected by culture techniques. These organisms occasionally occur in clinical material (28) . Their identification by the CAMP test (4) may be less accurate than by FA, since results from another study (unpublished data) indicate that one of four nonhemolytic group B streptococci tested did not enhance the hemolysis produced by staphylococcal beta hemolysin on sheep blood agar plates.
A method in which a carefully prepared and tested group B FA reagent is used has one important advantage over conventional cultureprecipitin methods. It requires much less time. A significant reduction in the time required to identify group B streptococci (several hours rather than several days) could mean more effective therapy for infants with neonatal meningitis. In addition, properly prepared type conjugates should allow typing of group B streptococci for epidemiological purposes.
The availability of these reagents commercially would determine the ultimate usefulness of group B immunofluorescence. Both group A conjugates and group B antisera vary in quality from commercial sources. Many "group B" 28, 1974 on November 6, 2017 by guest http://aem.asm.org/ Downloaded from antisera are type specific. We found one commercially prepared group B conjugate during our study; it was unsatisfactory in our tests.
